These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 28410300)

  • 1. Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma.
    Johanns TM; Dunn GP
    Cancer J; 2017; 23(2):125-130. PubMed ID: 28410300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.
    Johanns TM; Ward JP; Miller CA; Wilson C; Kobayashi DK; Bender D; Fu Y; Alexandrov A; Mardis ER; Artyomov MN; Schreiber RD; Dunn GP
    Cancer Immunol Res; 2016 Dec; 4(12):1007-1015. PubMed ID: 27799140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in immunotherapy for the treatment of glioblastoma.
    Tivnan A; Heilinger T; Lavelle EC; Prehn JH
    J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma.
    Luo D; Luo A; Hu S; Ye G; Li D; Zhao H; Peng B
    Sci Rep; 2024 Jul; 14(1):17630. PubMed ID: 39085480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological Aspects of Malignant Gliomas.
    Cohen-Inbar O; Zaaroor M
    Can J Neurol Sci; 2016 Jul; 43(4):494-502. PubMed ID: 27324313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solving the riddle of glioblastoma: The hope for immunotherapy.
    Bashir R; Mohile NA
    Neurology; 2016 Jun; 86(24):2220-1. PubMed ID: 27225224
    [No Abstract]   [Full Text] [Related]  

  • 8. Combining immunotherapy with radiation for the treatment of glioblastoma.
    Chow KK; Hara W; Lim M; Li G
    J Neurooncol; 2015 Jul; 123(3):459-64. PubMed ID: 25877468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for immunotherapy for treatment of glioblastoma.
    Lynes JP; Nwankwo AK; Sur HP; Sanchez VE; Sarpong KA; Ariyo OI; Dominah GA; Nduom EK
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32474411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma.
    Johanns TM; Garfinkle EAR; Miller KE; Livingstone AJ; Roberts KF; Rao Venkata LP; Dowling JL; Chicoine MR; Dacey RG; Zipfel GJ; Kim AH; Mardis ER; Dunn GP
    Clin Cancer Res; 2024 Jul; 30(13):2729-2742. PubMed ID: 38639919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in glioblastoma: emerging options in precision medicine.
    Hodges TR; Ferguson SD; Heimberger AB
    CNS Oncol; 2016 Jul; 5(3):175-86. PubMed ID: 27225028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
    Choi BD; Curry WT; Carter BS; Maus MV
    Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma.
    Lookian PP; Zhao D; Medina R; Wang H; Zenka J; Gilbert MR; Pacak K; Zhuang Z
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current challenges in designing GBM trials for immunotherapy.
    Weathers SP; Gilbert MR
    J Neurooncol; 2015 Jul; 123(3):331-7. PubMed ID: 25577401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma Immune Landscape and the Potential of New Immunotherapies.
    Daubon T; Hemadou A; Romero Garmendia I; Saleh M
    Front Immunol; 2020; 11():585616. PubMed ID: 33154756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulation for glioblastoma.
    Reardon DA; Wen PY; Wucherpfennig KW; Sampson JH
    Curr Opin Neurol; 2017 Jun; 30(3):361-369. PubMed ID: 28368867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cold Atmospheric Plasma as an Adjunct to Immunotherapy for Glioblastoma Multiforme.
    Almeida ND; Klein AL; Hogan EA; Terhaar SJ; Kedda J; Uppal P; Sack K; Keidar M; Sherman JH
    World Neurosurg; 2019 Oct; 130():369-376. PubMed ID: 31284051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.